Anal sac tumours of the dog and their response to cytoreductive surgery and chemotherapy.
A retrospective study of anal sac tumours without pulmonary metastases, from the author's clinical records for the period July 1989 to July 2002, was conducted to establish the response to treatment with surgery and melphalan chemotherapy. Of 21 dogs with tumours of the anal sacs 19 had apocrine gland adenocarcinomas of anal sac origin, one had a benign papillary cystadenoma and another had a malignant melanoma. Two of the 19 dogs had bilateral anal sac adenocarcinomas. Ten of the 19 dogs with apocrine gland adenocarcinomas of anal sac origin had sublumbar lymphadenopathy. Five dogs were excluded by their owners from recommended treatment. Fourteen dogs with apocrine gland adenocarcinomas of anal sac origin were treated by surgical cytoreduction and chemotherapy with melphalan. Seven of the 14 dogs had regional lymph node metastases. Cytoreduction was by local excision of the anal sac in all 14 dogs and concurrent removal of the sublumbar retroperitoneal lymph nodes in the seven dogs with regional lymph node metastases. The median survival time of dogs with sublumbar nodal metastasis was 20 months and for dogs with tumour localised to the anal sac the median survival time was 29.3 months. There was no difference in median survival of those dogs with sublumbar metastases compared to those without. This study suggests there is a role for melphalan in the treatment of dogs with anal sac adenocarcinoma when combined with cytoreductive surgery, with treatment survival times and the local recurrence rate of the primary tumour comparing favourably with previously published treatment regimes.
Camberwell Veterinary Clinic, 896 Riversdale Road, Camberwell, Victoria 3124.
S G
SG
Emms
D000230:Adenocarcinoma / Q000662:veterinary; D000694:Anal Gland Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000453:epidemiology* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D000695:Anal Sacs; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D003131:Combined Modality Therapy; D018292:Cystadenoma, Papillary / Q000662:veterinary; D004283:Dog Diseases / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000453:epidemiology* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D004285:Dogs; D005260:Female; D008297:Male; D008545:Melanoma / Q000662:veterinary; D009362:Neoplasm Metastasis; D011859:Radiography; D011996:Records / Q000662:veterinary; D012189:Retrospective Studies; D016019:Survival Analysis; D014739:Victoria / Q000453:epidemiology